$6.70
0.59% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US05380C1027
Symbol
RCEL
Sector

AVITA Therapeutics Stock price

$6.70
-2.40 26.37% 1M
-6.35 48.66% 6M
-6.10 47.66% YTD
-1.47 17.99% 1Y
+1.15 20.72% 3Y
-22.75 77.25% 5Y
+0.35 5.52% 10Y
NYSE, Closing price Tue, May 20 2025
-0.04 0.59%
ISIN
US05380C1027
Symbol
RCEL
Sector

Key metrics

Market capitalization $166.45m
Enterprise Value $184.70m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.58
P/S ratio (TTM) P/S ratio 2.32
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 41.35%
Revenue (TTM) Revenue $71.66m
EBIT (operating result TTM) EBIT $-51.19m
Free Cash Flow (TTM) Free Cash Flow $-45.99m
Cash position $25.82m
EPS (TTM) EPS $-2.19
P/E forward negative
P/S forward 1.69
EV/Sales forward 1.88
Short interest 11.34%
Show more

Is AVITA Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

AVITA Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a AVITA Therapeutics forecast:

5x Buy
63%
2x Hold
25%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a AVITA Therapeutics forecast:

Buy
63%
Hold
25%
Sell
13%

Financial data from AVITA Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
72 72
41% 41%
100%
- Direct Costs 10 10
36% 36%
15%
61 61
42% 42%
85%
- Selling and Administrative Expenses 90 90
40% 40%
125%
- Research and Development Expense 21 21
0% 0%
30%
-50 -50
61% 61%
-69%
- Depreciation and Amortization 1.41 1.41
5% 5%
2%
EBIT (Operating Income) EBIT -51 -51
61% 61%
-71%
Net Profit -57 -57
27% 27%
-80%

In millions USD.

Don't miss a Thing! We will send you all news about AVITA Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVITA Therapeutics Stock News

Neutral
Seeking Alpha
12 days ago
AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Chris Kallos - MST Access Operator Good day, and thank you for standing by. Welcome to ...
Neutral
GlobeNewsWire
12 days ago
VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025.
Neutral
GlobeNewsWire
about one month ago
VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025.
More AVITA Therapeutics News

Company Profile

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Head office United States
CEO James Corbett
Employees 260
Founded 1992
Website www.avitamedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today